USANA Health Sciences (USNA) Q1 Earnings and Revenues Surpass Estimates

Group 1: Earnings Performance - USANA Health Sciences reported quarterly earnings of $0.73 per share, exceeding the Zacks Consensus Estimate of $0.70 per share, but down from $0.86 per share a year ago, representing an earnings surprise of 4.29% [1] - The company posted revenues of $249.54 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.67%, compared to $227.8 million in the same quarter last year [2] - Over the last four quarters, USANA Health has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Group 2: Stock Performance and Outlook - USANA Health shares have declined approximately 33.6% since the beginning of the year, while the S&P 500 has decreased by 12.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.54 on revenues of $220.37 million, and for the current fiscal year, it is $2.59 on revenues of $941.62 million [7] - The estimate revisions trend for USANA Health is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Group 3: Industry Context - The Medical - Drugs industry, to which USANA Health belongs, is currently in the top 24% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]